Published in Diabetes Care on February 11, 2010
Epidemiology of Diabetes Interventions and Complications (EDIC) | NCT00360893
Proteomic Analysis in Paediatric Diabetes Type 1 (PAPD) (PAPD) | NCT04257877
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care (2014) 2.04
Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol (2010) 1.51
Corneal confocal microscopy detects early nerve regeneration in diabetic neuropathy after simultaneous pancreas and kidney transplantation. Diabetes (2012) 1.50
Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care (2014) 1.42
Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes (2013) 1.37
Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes (2013) 1.31
Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. Diabet Med (2011) 1.24
DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep (2010) 1.18
Reduced heart rate variability among youth with type 1 diabetes: the SEARCH CVD study. Diabetes Care (2012) 1.08
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care (2014) 1.07
Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. J Diabetes Complications (2013) 1.07
Vibration perception threshold as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the DCCT/EDIC study. Diabetes Care (2010) 1.05
"Unequivocally Abnormal" vs "Usual" Signs and Symptoms for Proficient Diagnosis of Diabetic Polyneuropathy: Cl vs N Phys Trial. Arch Neurol (2012) 1.04
Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain (2014) 0.99
Diabetic neuropathy part 1: overview and symmetric phenotypes. Neurol Clin (2013) 0.99
Corneal confocal microscopy to assess diabetic neuropathy: an eye on the foot. J Diabetes Sci Technol (2013) 0.98
Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy. Transl Res (2012) 0.97
Vascular memory: can we broaden the concept of the metabolic memory? Cardiovasc Diabetol (2012) 0.97
Altered excitation-inhibition balance in the brain of patients with diabetic neuropathy. Acad Radiol (2012) 0.97
Identification and prediction of diabetic sensorimotor polyneuropathy using individual and simple combinations of nerve conduction study parameters. PLoS One (2013) 0.96
Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC. Diabetes (2013) 0.96
Diabetic neuropathy: one disease or two? Curr Opin Neurol (2012) 0.95
Intensive diabetes therapy and ocular surgery in type 1 diabetes. N Engl J Med (2015) 0.94
Peripheral neuropathy in adolescents and young adults with type 1 and type 2 diabetes from the SEARCH for Diabetes in Youth follow-up cohort: a pilot study. Diabetes Care (2013) 0.93
Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep (2014) 0.93
Conduction slowing in diabetic sensorimotor polyneuropathy. Diabetes Care (2013) 0.92
Diabetes care, glycemic control, complications, and concomitant autoimmune diseases in children with type 1 diabetes in Turkey: a multicenter study. J Clin Res Pediatr Endocrinol (2013) 0.91
The association of skin intrinsic fluorescence with type 1 diabetes complications in the DCCT/EDIC study. Diabetes Care (2013) 0.91
Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes (2013) 0.88
Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control. Curr Clin Pharmacol (2011) 0.87
Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc (2011) 0.87
Unique responses of stem cell-derived vascular endothelial and mesenchymal cells to high levels of glucose. PLoS One (2012) 0.87
Lipids: A Suitable Therapeutic Target in Diabetic Neuropathy? J Diabetes Res (2017) 0.87
Treatment of diabetic sensory polyneuropathy. Curr Treat Options Neurol (2011) 0.86
Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis (2015) 0.86
Vascular stem cells in diabetic complications: evidence for a role in the pathogenesis and the therapeutic promise. Cardiovasc Diabetol (2012) 0.86
Differential reduction in corneal nerve fiber length in patients with type 1 or type 2 diabetes mellitus. J Diabetes Complications (2014) 0.85
Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep (2014) 0.85
Point-of-Care Hemoglobin A1c Testing: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2014) 0.85
Update on the management of diabetic polyneuropathies. Diabetes Metab Syndr Obes (2011) 0.85
Community screening for pre-diabetes and diabetes using HbA1c levels in high-risk African Americans and Latinos. Ethn Dis (2014) 0.83
Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care (2013) 0.82
Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care (2013) 0.82
Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes. BMJ Open (2015) 0.81
Pathways in the diagnosis and management of diabetic polyneuropathy. Curr Diab Rep (2015) 0.81
Adverse effect of high glucose concentration on stem cell therapy. Int J Hematol Oncol Stem Cell Res (2013) 0.81
The evolving natural history of neurophysiologic function in patients with well-controlled diabetes. J Peripher Nerv Syst (2013) 0.81
Small- and large-fiber neuropathy after 40 years of type 1 diabetes: associations with glycemic control and advanced protein glycation: the Oslo Study. Diabetes Care (2013) 0.81
One size does not fit all glycemic targets for type 2 diabetes. J Diabetes Investig (2014) 0.80
Measuring resource utilization in patient-oriented comparative effectiveness research: a psychometric study of the Resource Utilization Questionnaire. Res Theory Nurs Pract (2011) 0.80
Measurement of cooling detection thresholds for identification of diabetic sensorimotor polyneuropathy in type 1 diabetes. PLoS One (2014) 0.79
Evaluation of PMI-5011, an ethanolic extract of Artemisia dracunculus L., on peripheral neuropathy in streptozotocin-diabetic mice. Int J Mol Med (2011) 0.79
Symptoms of Eating Disorders and Depression in Emerging Adults with Early-Onset, Long-Duration Type 1 Diabetes and Their Association with Metabolic Control. PLoS One (2015) 0.79
Inflammation as a Therapeutic Target for Diabetic Neuropathies. Curr Diab Rep (2016) 0.78
Effects of intensive control of blood glucose and blood pressure on microvascular complications in patients with type II diabetes mellitus. Int J Ophthalmol (2013) 0.77
EMLA-Induced Skin Wrinkling for the Detection of Diabetic Neuropathy. Front Neurol (2013) 0.77
Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes. J Lipid Res (2015) 0.76
Time for a victory lap or time to raise the levees: a perspective on complication reduction and new-onset diabetes. Diabetes Care (2011) 0.75
Efficacy of insulin analogues in diabetic patients attending primary care centers. Saudi Med J (2015) 0.75
Insulin-ameliorated peripheral motor neuropathy in spontaneously diabetic WBN/Kob rats. J Vet Med Sci (2013) 0.75
Role of treatment-modifying MTHFR677C>T and 1298A>C polymorphisms in metformin-treated Puerto Rican patients with type-2 diabetes mellitus and peripheral neuropathy. Drug Metabol Personal Ther (2017) 0.75
Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study. J Diabetes Complications (2015) 0.75
Long-Term Impact of an Electronic Health Record-Enabled, Team-Based, and Scalable Population Health Strategy Based on the Chronic Care Model. AMIA Annu Symp Proc (2017) 0.75
Pharmacological treatment of diabetic peripheral neuropathy. P T (2015) 0.75
ACP Journal Club. Prior intensive insulin treatment reduced long-term risk for peripheral neuropathy in type 1 diabetes. Ann Intern Med (2010) 0.75
Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. Diabetes Care (2016) 0.75
Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. JAMA Ophthalmol (2016) 0.75
Point-of-Care Hemoglobin A1c Testing: A Budget Impact Analysis. Ont Health Technol Assess Ser (2014) 0.75
Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Care (2016) 0.75
Resilience in Vulnerable Populations With Type 2 Diabetes Mellitus and Hypertension: A Systematic Review and Meta-analysis. Can J Cardiol (2015) 0.75
Effects of Pomegranate Seed Oil on Metabolic State of Patients with Type 2 Diabetes Mellitus. Int J Prev Med (2016) 0.75
Can coefficient of variation of time-domain analysis be valuable for detecting cardiovascular autonomic neuropathy in young patients with type 1 diabetes: a case control study. BMC Cardiovasc Disord (2017) 0.75
Serum Phosphorylated Neurofilament-Heavy Chain, a Potential Biomarker, is Associated With Peripheral Neuropathy in Patients With Type 2 Diabetes. Medicine (Baltimore) (2015) 0.75
Treatment patterns and clinical characteristics of patients with type 2 diabetes mellitus according to body mass index: findings from an electronic medical records database. BMJ Open Diabetes Res Care (2017) 0.75
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med (2000) 10.05
Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care (1999) 8.33
Vascular risk factors and diabetic neuropathy. N Engl J Med (2005) 7.69
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA (2002) 6.61
Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol (2008) 3.83
The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med (1995) 3.71
Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care (1995) 2.67
Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care (2006) 2.64
Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol (1995) 2.47
Subclinical neuropathy among Diabetes Control and Complications Trial participants without diagnosable neuropathy at trial completion: possible predictors of incident neuropathy? Diabetes Care (2007) 1.25
Optimal blood glucose control during 18 years preserves peripheral nerve function in patients with 30 years' duration of type 1 diabetes. Diabetes Care (2003) 1.22
Effect of artificial pancreas treatment on peripheral nerve function in diabetes. Neurology (1981) 1.15
Diabetic peripheral neuropathies: their cost to patient and society and the value of knowledge of risk factors for development of interventions. Eur Neurol (1999) 0.99
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med (2000) 10.05
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20
Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care (2007) 8.43
Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care (2005) 7.81
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med (2011) 7.42
Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care (2006) 7.09
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med (2009) 6.89
Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med (2004) 6.77
A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab (2008) 4.97
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes (2004) 4.44
Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis (2002) 4.34
Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care (2003) 4.22
Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol (2008) 3.83
Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care (2006) 3.47
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 3.45
Perspective: Transforming science into medicine: how clinician-scientists can build bridges across research's "valley of death". Acad Med (2012) 3.43
The direct medical cost of type 2 diabetes. Diabetes Care (2003) 3.23
Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med (2011) 3.20
Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol (2006) 3.12
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care (2008) 2.87
Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study. Diabetes Care (2006) 2.84
Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev (2004) 2.83
A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care (2007) 2.67
Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care (2006) 2.64
Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev (2011) 2.61
The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes (2008) 2.60
Diabetic neuropathy: mechanisms to management. Pharmacol Ther (2008) 2.57
Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care (2010) 2.57
Valuing health-related quality of life in diabetes. Diabetes Care (2002) 2.55
Glycated hemoglobin assessment in clinical practice: comparison of the A1cNow point-of-care device with central laboratory testing (GOAL A1C Study). Diabetes Technol Ther (2005) 2.54
Kindlin-2 is an essential component of intercalated discs and is required for vertebrate cardiac structure and function. Circ Res (2008) 2.48
Diabetes reporting as a cause of death: results from the Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care (2006) 2.36
Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathy. PLoS Genet (2009) 2.23
Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care (2007) 2.20
High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J (2002) 2.18
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2013) 2.15
Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care (2010) 2.15
Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care (2008) 2.04
Opportunistic screening for diabetes in routine clinical practice. Diabetes Care (2004) 2.03
Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med (2008) 2.01
Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes (2009) 1.99
Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol (2012) 1.99
Risk factors for mortality among patients with diabetes: the Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care (2007) 1.95
Stem cell technology for neurodegenerative diseases. Ann Neurol (2011) 1.93
A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care (2005) 1.92
Microvascular complications of impaired glucose tolerance. Diabetes (2003) 1.88
Sexual dysfunction in women with type 1 diabetes: long-term findings from the DCCT/ EDIC study cohort. Diabetes Care (2009) 1.87
Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells (2012) 1.87
Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol (2011) 1.85
Aligned electrospun nanofibers specify the direction of dorsal root ganglia neurite growth. J Biomed Mater Res A (2007) 1.83
A multivariate logistic regression equation to screen for diabetes: development and validation. Diabetes Care (2002) 1.83
Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes (2014) 1.81
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care (2013) 1.79
Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study. J Diabetes Complications (2008) 1.77
Mouse models of diabetic neuropathy. Neurobiol Dis (2007) 1.76
Association between iron deficiency and A1C Levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care (2010) 1.75
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes (2006) 1.75
Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J (2005) 1.75
Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes (2010) 1.73
Impact of a preconception counseling program for teens with type 1 diabetes (READY-Girls) on patient-provider interaction, resource utilization, and cost. Diabetes Care (2010) 1.66
A genome-wide association study identifies a novel major locus for glycemic control in type 1 diabetes, as measured by both A1C and glucose. Diabetes (2009) 1.65
Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. Curr Med Res Opin (2006) 1.65
Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes (2009) 1.64
Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev (2011) 1.62
How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol (2010) 1.60
Impact of diabetes and its treatment on cognitive function among adolescents who participated in the Diabetes Control and Complications Trial. Diabetes Care (2008) 1.58
Predictors of mortality over 8 years in type 2 diabetic patients: Translating Research Into Action for Diabetes (TRIAD). Diabetes Care (2012) 1.58
Rapid, noninvasive detection of diabetes-induced retinal metabolic stress. Arch Ophthalmol (2008) 1.57
Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol (2006) 1.56
Control of cell survival by IGF signaling pathways. Growth Horm IGF Res (2002) 1.56